Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2025
Principal Event: Entry into a Sixth Amendment to the Credit Agreement dated December 22, 2020.
Key Financial Metrics and Debt Status
- Debt Covenant Waivers: Lenders waived events of default regarding failure to achieve refinancing milestones and non-compliance with consolidated net leverage and fixed charge coverage ratios as of June 30, 2025.
- Interest Rate Adjustment: The applicable interest rate margin was increased to SOFR plus 700 basis points.
- Liquidity Requirement: The Company must maintain minimum liquidity of $3.0 million (defined as unrestricted cash plus undrawn revolver capacity) to avoid default.
- Amendment Fees: Total fees of $0.4 million (1.00% of outstanding debt). 25% paid upon signing; 75% payable upon refinancing, repayment, or an event of default.
- Refinancing Deadline: Mandatory steps toward refinancing or repayment must be completed by December 5, 2025.
Material Changes and Going Concern Status
The filing discloses a material deterioration in the Company's financial position. The Company has failed to meet previous refinancing milestones and financial covenants. Consequently, management has expressed substantial doubt about the Company's ability to continue as a going concern. The Company states that based on anticipated cash flows from operations, it will be unable to pay debt obligations and fund operations beyond the December 5, 2025 deadline unless it accesses other sources of capital or extends the repayment date.
Guidance, Risks, and Contingencies
- Capital Access Uncertainty: The Company is exploring alternative capital sources but notes that availability, terms, and sufficiency of funds are uncertain.
- Default Triggers: Failure to accomplish refinancing steps by December 5, 2025, constitutes an event of default. Additionally, failure to maintain the $3.0 million liquidity threshold or comply with payment obligations will trigger default.
- Mandatory Prepayment: The amendment adds mandatory prepayment events upon receipt of cash proceeds from a refinancing or the sale of equity interests/assets.
- Forward-Looking Statements: The filing includes standard disclaimers regarding uncertainties in future performance and the ability to fund operations.
Investor Verification Checklist
- Verify the Company's current unrestricted cash balance and undrawn revolver capacity to confirm compliance with the $3.0 million liquidity covenant.
- Monitor progress on refinancing efforts leading up to the December 5, 2025 deadline.
- Review the full text of the Sixth Amendment (Exhibit 10.1) for specific terms regarding the increased interest rate and prepayment conditions.
- Assess the likelihood of accessing new capital given the stated "substantial doubt" regarding going concern status.
- Check for any subsequent filings regarding the payment of the remaining 75% of the amendment fee or further covenant waivers.